There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN), Coherus Biosciences (CHRS) and Fate Therapeutics (FATE) with bullish sentiments.
Agenus (AGEN)
In a report issued on September 18, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Agenus, with a price target of $8.00. The company’s shares closed last Wednesday at $4.29.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 17.6% and a 47.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Agenus is a Strong Buy with an average price target of $8.00, an 88.2% upside from current levels. In a report issued on September 18, Jefferies also maintained a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
Coherus Biosciences (CHRS)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences yesterday and set a price target of $35.00. The company’s shares closed last Wednesday at $18.19.
According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -4.3% and a 46.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Wave Life Sciences, and Gilead Sciences.
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $29.17.
Fate Therapeutics (FATE)
Oppenheimer analyst Matthew Biegler assigned a Buy rating to Fate Therapeutics today and set a price target of $40.00. The company’s shares closed last Wednesday at $36.47, close to its 52-week high of $39.45.
According to TipRanks.com, Biegler is a 4-star analyst with an average return of 26.9% and a 55.2% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Aptose Biosciences, and Homology Medicines.
Currently, the analyst consensus on Fate Therapeutics is a Strong Buy with an average price target of $39.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
